Raludotatug deruxtecan clinical trials
Also written DS-6000a and MK-5909.
ClinicalTrials.gov finds 10 studies for raludotatug deruxtecan. How that becomes 11 here
Every study that search finds has been read, to see whether and how it gives raludotatug deruxtecan. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 10Found by its intervention search · See all 10 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 6 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- +1Give it under a name that search misses: a biosimilar’s code or a misspelling
- 11Give raludotatug deruxtecan to participants
- 11Test it: the count on this site
Get an email when these change. Save the raludotatug deruxtecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2025 (5); 1 more planned to start later
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Often tested with
Tested in the same studies.
Ifinatamab deruxtecan (2) · 5-HT3 antagonists (1) · NK1 receptor antagonists (1) · Pembrolizumab/Quavonlimab MK-1308A (1) · Anti-ILT4 Monoclonal Antibody MK-4830 (1) · Favezelimab/Pembrolizumab Formulation (1) · Carboplatin (1) · Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test raludotatug deruxtecan.
- Dec 2026A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian TumorsPhase 1 · Daiichi Sankyo
Studies
Open first, then newest update. How each study uses raludotatug deruxtecan has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 11
- A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)Not yet recruitingPhase 3Daiichi SankyoNCT07791732With or without bevacizumab as maintenance in platinum-sensitive ovarian cancerWritten as R-DXdReport a problem
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06843447With chemotherapy, bevacizumab or pembrolizumab in ovarian cancerWritten as Raludotatug DeruxtecanReport a problem
- Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06780098Alone in one arm, previously treated squamous lung cancerWritten as R-DXDReport a problem
- A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07743164With or without bevacizumab, against chemotherapy after a PARP inhibitorWritten as R-DXdReport a problem
- A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07776691With or without bevacizumab as first maintenance in ovarian cancerWritten as R-DXdReport a problem
- A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube CancerRecruitingPhase 2/3Daiichi SankyoNCT06161025Against chemotherapy in platinum-resistant ovarian cancerWritten as R-DXdReport a problem
- A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06780085Alone in one arm, previously treated non-squamous lung cancerWritten as Raludotatug DeruxtecanReport a problem
- A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)Active, not recruitingPhase 2Daiichi SankyoNCT06660654Alone across CDH6-expressing solid tumoursWritten as Raludotatug deruxtecanReport a problem
- A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian TumorsActive, not recruitingPhase 1Daiichi SankyoNCT04707248Alone in kidney and ovarian cancer, first in peopleWritten as DS-6000aReport a problem
- Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Active, not recruitingPhase 1/2Merck Sharp & Dohme LLCNCT04938817Alone in one arm, small cell lung cancer after PD-1 therapyWritten as R-DXdReport a problem
- A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06864169Alone in digestive cancersWritten as Raludotatug Deruxtecan (R-DXd)Report a problem
Tested on its own · 4 — no other medicine in its arm
- A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube CancerRecruitingPhase 2/3Daiichi SankyoNCT06161025Against chemotherapy in platinum-resistant ovarian cancerWritten as R-DXdReport a problem
- A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)Active, not recruitingPhase 2Daiichi SankyoNCT06660654Alone across CDH6-expressing solid tumoursWritten as Raludotatug deruxtecanReport a problem
- A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian TumorsActive, not recruitingPhase 1Daiichi SankyoNCT04707248Alone in kidney and ovarian cancer, first in peopleWritten as DS-6000aReport a problem
- A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06864169Alone in digestive cancersWritten as Raludotatug Deruxtecan (R-DXd)Report a problem
Tested with established drugs · 3 — they are given beside it
- A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)Not yet recruitingPhase 3Daiichi SankyoNCT07791732With or without bevacizumab as maintenance in platinum-sensitive ovarian cancerWritten as R-DXdReport a problem
- A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07743164With or without bevacizumab, against chemotherapy after a PARP inhibitorWritten as R-DXdReport a problem
- A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07776691With or without bevacizumab as first maintenance in ovarian cancerWritten as R-DXdReport a problem
Tested in a combination · 4 — another drug in the study is under test too
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06843447With chemotherapy, bevacizumab or pembrolizumab in ovarian cancerWritten as Raludotatug DeruxtecanReport a problem
- Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06780098Alone in one arm, previously treated squamous lung cancerWritten as R-DXDReport a problem
- A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06780085Alone in one arm, previously treated non-squamous lung cancerWritten as Raludotatug DeruxtecanReport a problem
- Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Active, not recruitingPhase 1/2Merck Sharp & Dohme LLCNCT04938817Alone in one arm, small cell lung cancer after PD-1 therapyWritten as R-DXdReport a problem
Codes
What other systems call raludotatug deruxtecan · ClinicalTrials.gg INT016128
- UNII (FDA) BPQ010OFD7RALUDOTATUG DERUXTECANOne source FDA
- NCI Thesaurus C179214Raludotatug DeruxtecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | BPQ010OFD7 | RALUDOTATUG DERUXTECAN | One source FDA |
| NCI Thesaurus | C179214 | Raludotatug Deruxtecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.